Overall, ADAM10 inhibitor treatment results in the restoration of membrane CD30 levels, which restored sensitivity to anti-CD30 monoclonal therapies used in HL, such as Iratumumab (64). The gene discussed is ADAM10; the disease is Hodgkins lymphoma.